HopeStage
Back to all studies
CompletedNCT02079844

Roflumilast Added to Antipsychotic Medication for Thinking Difficulties in Schizophrenia

About this titleRead the official source — NCT02079844
Medication studyAges 18–55United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Denmark HillSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2014
Recruitment status
Completed
Enrollment listed in the registry
20
Sponsor
Takeda
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 55 Years
Official registry ID
NCT02079844
Official title
Show the full official title

A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Denmark Hill

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Takeda.

Did this study involve medication?

Yes. The study involved medication, including Roflumilast, Placebo and Second generation antipsychotic.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies